Clinical Trial Update: A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta [Phase 1]

View source ↗

Summary

Phase 1 postmarketing transfer study evaluating Cimzia (certolizumab pegol) from mother to infant via placenta has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Axial Spondyloarthritis
• Crohn Disease
• Non-radiographic Axial Spondyloarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

Sponsor: UCB BIOSCIENCES, Inc. | Conditions: Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA | Phase 1 | Status: COMPLETED | Results posted: 2019-06-21